Methods of maintaining, expanding and differentiating neuronal subtype specific progenitors
Methods for expanding proliferating populations of neuronal subtype-specific progenitors and creating substantially pure populations of motor neurons are provided herein. In particular, the present invention provides methods for maintaining the unique gene profile and differentiation potential of neuronal subtype-specific progenitors, such as motor neuron progenitors and hindbrain serotonergic neural progenitors.
1. A method of generating populations of motor neuron progenitor cells from neural stem cells, comprising the steps of
(a) culturing neural stem cells in a culture medium comprising:
a Wnt signaling pathway agonist, wherein the Wnt signaling pathway agonist is a GSK3 inhibitor selected from the group consisting of CHIR99021 and 6-bromo-iridium-3′-oxime, and wherein the Wnt signaling pathway agonist is used at a concentration of about 1 μM to 3 μM,
a bone morphogenetic protein (BMP) signaling pathway inhibitor selected from the group consisting of DMH-1, Dorsomorphin, and LDN-193189, wherein the concentration of the BMP signaling pathway inhibitor is about 1 μM to 5 μM,
an inhibitor of activin-nodal signaling, wherein the inhibitor of activin-nodal signaling is SB431542 in an amount of about 1 μM to 5 μM,
retinoic acid in an amount of about 0.1 μM to 1 μM, and
purmorphamine in an amount of about 0.1 μM to about 1 μM,
(b) detecting within the cultured cells of step (a) a population positive for Olig2 and negative for Nkx2.2, wherein a population of at least 85% pure Olig2±/Nkx2.2− motor neuron progenitor cells is obtained.
2. The method of claim 1 , further comprising the step of
(c) culturing the Olig2+/Nkx2.2− motor neuron progenitor cells in a medium comprising retinoic acid, purmorphamine and a Notch signaling inhibitor, wherein the Notch inhibitor is selected from the group consisting of (S,S)-2-[2-(3,5-Difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide (compound E), N-[(3,5-Difluorophenyl)acetyl]-L-alanyl-2-phenyl]glycine-1,1-dimethylethyl ester (DAPT), and Dibenzazepine (DBZ),
(b) detecting MNX1 and ChAT markers on the cells cultured in step (c), wherein a population of at least 80% pure MNX1+/ChAT+motor neurons is obtained.
3. The method of claim 1 , wherein the Wnt signaling pathway agonist is CHIR99021.
4. The method of claim 1 , wherein the concentration of the Wnt signaling pathway agonist is about 1 μM.
5. The method of claim 2 , wherein the Notch signaling pathway inhibitor is (S,S)-2-[2-(3,5-Difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide (compound E).
6. The method of claim 2 , wherein the culture medium comprises 0.01 μM-1 μM retinoic acid, 0.01 μM-0.5 μM purmorphamine, and 0.05 μM-0.5 μM compound E.